Comorbidities included hypertensive diseases (I10-I16), Type 2 diabetes mellitus (E11), chronic lower respiratory diseases (J40-J47), neoplasms (C00-D49), psychoactive substance use (F10-F19), ischemic heart diseases (I20-I25), chronic kidney disease (N18), and cerebrovascular diseases (I60-I69)
The downsides are significant
The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
Thats a user population that includes not only weight lifters and bodybuilders but also people at risk for: Sarcopenia The worldwide prevalence of sarcopenia, or age-related muscle loss, is 10-16%, so its far from uncommon.31 And because people begin to lose 3-8% of their existing muscle mass with every proceeding decade of adult life, it behooves you to take active measures to preserve the lean mass you have.32 Otherwise, you may find yourself struggling with physical weakness and decreased physiological function as you grow older.33 Resistance training can mitigate the risk, and a growth hormone secretagogue peptide can support your resistance training
References Risbud MV, Schaer TP, Shapiro IM: Toward an understanding of the role of notochordal cells in the adult intervertebral disc: from discord to accord
